2种药物治疗下呼吸道感染的成本-效果分析

The cost-effectiveness analysis of two drugs for lower respiratory tract infections

目的评价头孢噻肟钠和头孢哌酮钠治疗下呼吸道感染的经济学效果。方法73例下呼吸道感染患者随机分为A组39例和B组34例,分别给予头孢噻肟钠和头孢哌酮钠治疗,观察2组疗效、不良反应,运用药物经济学成本-效果分析法进行最小成本分析。结果A组和B组治疗下呼吸道感染总有效率分别为94.87%和97.05%,差异无统计学意义(P>0.05);治疗成本分别为695.56元和1 379.24元;A组成本效果比(C/E)为1.50,B组C/E为9.03。结论使用头孢噻肟钠下呼吸道感染是一种较好方案,符合药物经济学原则。

Objective To evaluate the pharmacoeconomic effectiveness of cefotaxime sodium and cefoperazone sodium for lower respiratory tract infections.Methods A total of 73 patients with lower respiratory infections were randomly assigned to receive cefotaxime sodium of 39 cases（group A）,cefoperazone sodium of 34 cases（group B）,the efficacies and adverse drug reactions（ADRs）of the two groups were monitored and on which cost minimization analyses were performed.Results The total effective rates of group A,and B were 94.87% and 97.05% respectively,effectiveness of the two groups was compared and the difference was not significant（P〉0.05）;The total cost of the two groups were 695.56 yuan and 1 379.24 yuan respectively.The cost effectiveness rates（C/E）of group A and B were 1.50 and 9.03 respectively.Conclusion Cefotaxime sodium is the optimal one for lower respiratory infection in pharmacoeconomics.